
Global Uric Acid-lowering Drugs Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Uric Acid-lowering Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Uric Acid-lowering Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Uric Acid-lowering Drugs market include Takeda Pharmaceuticals, Teva, Sanwa Kagaku Kenkyusho, Sanofi, GSK, AstraZeneca, Towa Pharmaceutical, Toa Eiyo and Mylan Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Uric Acid-lowering Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Uric Acid-lowering Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Uric Acid-lowering Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Uric Acid-lowering Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Uric Acid-lowering Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Uric Acid-lowering Drugs sales, projected growth trends, production technology, application and end-user industry.
Uric Acid-lowering Drugs Segment by Company
Takeda Pharmaceuticals
Teva
Sanwa Kagaku Kenkyusho
Sanofi
GSK
AstraZeneca
Towa Pharmaceutical
Toa Eiyo
Mylan Pharmaceuticals
Mochida Pharmaceutical
Lannett Company
Horizon Therapeutics
Fuji Yakuhin
Uric Acid-lowering Drugs Segment by Type
Uric Acid Production Inhibitors
Uric Acid Dissolving Agents
Urate-stimulating Excretion Agents
Uric Acid-lowering Drugs Segment by Application
Hyperuricemia
Uric Acid Kidney Stones
Gout
Other
Uric Acid-lowering Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Uric Acid-lowering Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Uric Acid-lowering Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Uric Acid-lowering Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Uric Acid-lowering Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Uric Acid-lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Uric Acid-lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Uric Acid-lowering Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Uric Acid-lowering Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Uric Acid-lowering Drugs industry.
Chapter 3: Detailed analysis of Uric Acid-lowering Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Uric Acid-lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Uric Acid-lowering Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
According to APO Research, the global Uric Acid-lowering Drugs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Asia-Pacific market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Uric Acid-lowering Drugs market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The Europe market for Uric Acid-lowering Drugs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Uric Acid-lowering Drugs market include Takeda Pharmaceuticals, Teva, Sanwa Kagaku Kenkyusho, Sanofi, GSK, AstraZeneca, Towa Pharmaceutical, Toa Eiyo and Mylan Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Uric Acid-lowering Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Uric Acid-lowering Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Uric Acid-lowering Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Uric Acid-lowering Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Uric Acid-lowering Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Uric Acid-lowering Drugs sales, projected growth trends, production technology, application and end-user industry.
Uric Acid-lowering Drugs Segment by Company
Takeda Pharmaceuticals
Teva
Sanwa Kagaku Kenkyusho
Sanofi
GSK
AstraZeneca
Towa Pharmaceutical
Toa Eiyo
Mylan Pharmaceuticals
Mochida Pharmaceutical
Lannett Company
Horizon Therapeutics
Fuji Yakuhin
Uric Acid-lowering Drugs Segment by Type
Uric Acid Production Inhibitors
Uric Acid Dissolving Agents
Urate-stimulating Excretion Agents
Uric Acid-lowering Drugs Segment by Application
Hyperuricemia
Uric Acid Kidney Stones
Gout
Other
Uric Acid-lowering Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Uric Acid-lowering Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Uric Acid-lowering Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Uric Acid-lowering Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Uric Acid-lowering Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Uric Acid-lowering Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Uric Acid-lowering Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Uric Acid-lowering Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Uric Acid-lowering Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Uric Acid-lowering Drugs industry.
Chapter 3: Detailed analysis of Uric Acid-lowering Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Uric Acid-lowering Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Uric Acid-lowering Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
Table of Contents
199 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Uric Acid-lowering Drugs Sales Value (2020-2031)
- 1.2.2 Global Uric Acid-lowering Drugs Sales Volume (2020-2031)
- 1.2.3 Global Uric Acid-lowering Drugs Sales Average Price (2020-2031)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
- 2 Uric Acid-lowering Drugs Market Dynamics
- 2.1 Uric Acid-lowering Drugs Industry Trends
- 2.2 Uric Acid-lowering Drugs Industry Drivers
- 2.3 Uric Acid-lowering Drugs Industry Opportunities and Challenges
- 2.4 Uric Acid-lowering Drugs Industry Restraints
- 3 Uric Acid-lowering Drugs Market by Company
- 3.1 Global Uric Acid-lowering Drugs Company Revenue Ranking in 2024
- 3.2 Global Uric Acid-lowering Drugs Revenue by Company (2020-2025)
- 3.3 Global Uric Acid-lowering Drugs Sales Volume by Company (2020-2025)
- 3.4 Global Uric Acid-lowering Drugs Average Price by Company (2020-2025)
- 3.5 Global Uric Acid-lowering Drugs Company Ranking (2023-2025)
- 3.6 Global Uric Acid-lowering Drugs Company Manufacturing Base and Headquarters
- 3.7 Global Uric Acid-lowering Drugs Company Product Type and Application
- 3.8 Global Uric Acid-lowering Drugs Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Uric Acid-lowering Drugs Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.9.3 2024 Uric Acid-lowering Drugs Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
- 4 Uric Acid-lowering Drugs Market by Type
- 4.1 Uric Acid-lowering Drugs Type Introduction
- 4.1.1 Uric Acid Production Inhibitors
- 4.1.2 Uric Acid Dissolving Agents
- 4.1.3 Urate-stimulating Excretion Agents
- 4.2 Global Uric Acid-lowering Drugs Sales Volume by Type
- 4.2.1 Global Uric Acid-lowering Drugs Sales Volume by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Uric Acid-lowering Drugs Sales Volume by Type (2020-2031)
- 4.2.3 Global Uric Acid-lowering Drugs Sales Volume Share by Type (2020-2031)
- 4.3 Global Uric Acid-lowering Drugs Sales Value by Type
- 4.3.1 Global Uric Acid-lowering Drugs Sales Value by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Uric Acid-lowering Drugs Sales Value by Type (2020-2031)
- 4.3.3 Global Uric Acid-lowering Drugs Sales Value Share by Type (2020-2031)
- 5 Uric Acid-lowering Drugs Market by Application
- 5.1 Uric Acid-lowering Drugs Application Introduction
- 5.1.1 Hyperuricemia
- 5.1.2 Uric Acid Kidney Stones
- 5.1.3 Gout
- 5.1.4 Other
- 5.2 Global Uric Acid-lowering Drugs Sales Volume by Application
- 5.2.1 Global Uric Acid-lowering Drugs Sales Volume by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Uric Acid-lowering Drugs Sales Volume by Application (2020-2031)
- 5.2.3 Global Uric Acid-lowering Drugs Sales Volume Share by Application (2020-2031)
- 5.3 Global Uric Acid-lowering Drugs Sales Value by Application
- 5.3.1 Global Uric Acid-lowering Drugs Sales Value by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Uric Acid-lowering Drugs Sales Value by Application (2020-2031)
- 5.3.3 Global Uric Acid-lowering Drugs Sales Value Share by Application (2020-2031)
- 6 Uric Acid-lowering Drugs Regional Sales and Value Analysis
- 6.1 Global Uric Acid-lowering Drugs Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Uric Acid-lowering Drugs Sales by Region (2020-2031)
- 6.2.1 Global Uric Acid-lowering Drugs Sales by Region: 2020-2025
- 6.2.2 Global Uric Acid-lowering Drugs Sales by Region (2026-2031)
- 6.3 Global Uric Acid-lowering Drugs Sales Value by Region: 2020 VS 2024 VS 2031
- 6.4 Global Uric Acid-lowering Drugs Sales Value by Region (2020-2031)
- 6.4.1 Global Uric Acid-lowering Drugs Sales Value by Region: 2020-2025
- 6.4.2 Global Uric Acid-lowering Drugs Sales Value by Region (2026-2031)
- 6.5 Global Uric Acid-lowering Drugs Market Price Analysis by Region (2020-2025)
- 6.6 North America
- 6.6.1 North America Uric Acid-lowering Drugs Sales Value (2020-2031)
- 6.6.2 North America Uric Acid-lowering Drugs Sales Value Share by Country, 2024 VS 2031
- 6.7 Europe
- 6.7.1 Europe Uric Acid-lowering Drugs Sales Value (2020-2031)
- 6.7.2 Europe Uric Acid-lowering Drugs Sales Value Share by Country, 2024 VS 2031
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Uric Acid-lowering Drugs Sales Value (2020-2031)
- 6.8.2 Asia-Pacific Uric Acid-lowering Drugs Sales Value Share by Country, 2024 VS 2031
- 6.9 South America
- 6.9.1 South America Uric Acid-lowering Drugs Sales Value (2020-2031)
- 6.9.2 South America Uric Acid-lowering Drugs Sales Value Share by Country, 2024 VS 2031
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Uric Acid-lowering Drugs Sales Value (2020-2031)
- 6.10.2 Middle East & Africa Uric Acid-lowering Drugs Sales Value Share by Country, 2024 VS 2031
- 7 Uric Acid-lowering Drugs Country-level Sales and Value Analysis
- 7.1 Global Uric Acid-lowering Drugs Sales by Country: 2020 VS 2024 VS 2031
- 7.2 Global Uric Acid-lowering Drugs Sales Value by Country: 2020 VS 2024 VS 2031
- 7.3 Global Uric Acid-lowering Drugs Sales by Country (2020-2031)
- 7.3.1 Global Uric Acid-lowering Drugs Sales by Country (2020-2025)
- 7.3.2 Global Uric Acid-lowering Drugs Sales by Country (2026-2031)
- 7.4 Global Uric Acid-lowering Drugs Sales Value by Country (2020-2031)
- 7.4.1 Global Uric Acid-lowering Drugs Sales Value by Country (2020-2025)
- 7.4.2 Global Uric Acid-lowering Drugs Sales Value by Country (2026-2031)
- 7.5 USA
- 7.5.1 USA Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.5.2 USA Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.5.3 USA Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.6 Canada
- 7.6.1 Canada Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Canada Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Canada Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.7 Mexico
- 7.6.1 Mexico Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.6.2 Mexico Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Mexico Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.8 Germany
- 7.8.1 Germany Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.8.2 Germany Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.8.3 Germany Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.9 France
- 7.9.1 France Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.9.2 France Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.9.3 France Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.10 U.K.
- 7.10.1 U.K. Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.10.2 U.K. Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.10.3 U.K. Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.11 Italy
- 7.11.1 Italy Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.11.2 Italy Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Italy Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.12 Spain
- 7.12.1 Spain Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.12.2 Spain Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Spain Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.13 Russia
- 7.13.1 Russia Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.13.2 Russia Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Russia Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.14 Netherlands
- 7.14.1 Netherlands Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.14.2 Netherlands Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.14.3 Netherlands Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.15.2 Nordic Countries Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Nordic Countries Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.16 China
- 7.16.1 China Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.16.2 China Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.16.3 China Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.17 Japan
- 7.17.1 Japan Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.17.2 Japan Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.17.3 Japan Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.18 South Korea
- 7.18.1 South Korea Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.18.2 South Korea Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.18.3 South Korea Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.19 India
- 7.19.1 India Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.19.2 India Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.19.3 India Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.20 Australia
- 7.20.1 Australia Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.20.2 Australia Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Australia Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.21.2 Southeast Asia Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Southeast Asia Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.22 Brazil
- 7.22.1 Brazil Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.22.2 Brazil Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Brazil Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.23 Argentina
- 7.23.1 Argentina Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.23.2 Argentina Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Argentina Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.24 Chile
- 7.24.1 Chile Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.24.2 Chile Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Chile Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.25 Colombia
- 7.25.1 Colombia Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.25.2 Colombia Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Colombia Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.26 Peru
- 7.26.1 Peru Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.26.2 Peru Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Peru Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.27.2 Saudi Arabia Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.27.3 Saudi Arabia Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.28 Israel
- 7.28.1 Israel Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.28.2 Israel Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Israel Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.29 UAE
- 7.29.1 UAE Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.29.2 UAE Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.29.3 UAE Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.30 Turkey
- 7.30.1 Turkey Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.30.2 Turkey Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Turkey Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.31 Iran
- 7.31.1 Iran Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.31.2 Iran Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.31.3 Iran Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 7.32 Egypt
- 7.32.1 Egypt Uric Acid-lowering Drugs Sales Value Growth Rate (2020-2031)
- 7.32.2 Egypt Uric Acid-lowering Drugs Sales Value Share by Type, 2024 VS 2031
- 7.32.3 Egypt Uric Acid-lowering Drugs Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Takeda Pharmaceuticals
- 8.1.1 Takeda Pharmaceuticals Comapny Information
- 8.1.2 Takeda Pharmaceuticals Business Overview
- 8.1.3 Takeda Pharmaceuticals Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.1.4 Takeda Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio
- 8.1.5 Takeda Pharmaceuticals Recent Developments
- 8.2 Teva
- 8.2.1 Teva Comapny Information
- 8.2.2 Teva Business Overview
- 8.2.3 Teva Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.2.4 Teva Uric Acid-lowering Drugs Product Portfolio
- 8.2.5 Teva Recent Developments
- 8.3 Sanwa Kagaku Kenkyusho
- 8.3.1 Sanwa Kagaku Kenkyusho Comapny Information
- 8.3.2 Sanwa Kagaku Kenkyusho Business Overview
- 8.3.3 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.3.4 Sanwa Kagaku Kenkyusho Uric Acid-lowering Drugs Product Portfolio
- 8.3.5 Sanwa Kagaku Kenkyusho Recent Developments
- 8.4 Sanofi
- 8.4.1 Sanofi Comapny Information
- 8.4.2 Sanofi Business Overview
- 8.4.3 Sanofi Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.4.4 Sanofi Uric Acid-lowering Drugs Product Portfolio
- 8.4.5 Sanofi Recent Developments
- 8.5 GSK
- 8.5.1 GSK Comapny Information
- 8.5.2 GSK Business Overview
- 8.5.3 GSK Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.5.4 GSK Uric Acid-lowering Drugs Product Portfolio
- 8.5.5 GSK Recent Developments
- 8.6 AstraZeneca
- 8.6.1 AstraZeneca Comapny Information
- 8.6.2 AstraZeneca Business Overview
- 8.6.3 AstraZeneca Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.6.4 AstraZeneca Uric Acid-lowering Drugs Product Portfolio
- 8.6.5 AstraZeneca Recent Developments
- 8.7 Towa Pharmaceutical
- 8.7.1 Towa Pharmaceutical Comapny Information
- 8.7.2 Towa Pharmaceutical Business Overview
- 8.7.3 Towa Pharmaceutical Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.7.4 Towa Pharmaceutical Uric Acid-lowering Drugs Product Portfolio
- 8.7.5 Towa Pharmaceutical Recent Developments
- 8.8 Toa Eiyo
- 8.8.1 Toa Eiyo Comapny Information
- 8.8.2 Toa Eiyo Business Overview
- 8.8.3 Toa Eiyo Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.8.4 Toa Eiyo Uric Acid-lowering Drugs Product Portfolio
- 8.8.5 Toa Eiyo Recent Developments
- 8.9 Mylan Pharmaceuticals
- 8.9.1 Mylan Pharmaceuticals Comapny Information
- 8.9.2 Mylan Pharmaceuticals Business Overview
- 8.9.3 Mylan Pharmaceuticals Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.9.4 Mylan Pharmaceuticals Uric Acid-lowering Drugs Product Portfolio
- 8.9.5 Mylan Pharmaceuticals Recent Developments
- 8.10 Mochida Pharmaceutical
- 8.10.1 Mochida Pharmaceutical Comapny Information
- 8.10.2 Mochida Pharmaceutical Business Overview
- 8.10.3 Mochida Pharmaceutical Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.10.4 Mochida Pharmaceutical Uric Acid-lowering Drugs Product Portfolio
- 8.10.5 Mochida Pharmaceutical Recent Developments
- 8.11 Lannett Company
- 8.11.1 Lannett Company Comapny Information
- 8.11.2 Lannett Company Business Overview
- 8.11.3 Lannett Company Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.11.4 Lannett Company Uric Acid-lowering Drugs Product Portfolio
- 8.11.5 Lannett Company Recent Developments
- 8.12 Horizon Therapeutics
- 8.12.1 Horizon Therapeutics Comapny Information
- 8.12.2 Horizon Therapeutics Business Overview
- 8.12.3 Horizon Therapeutics Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.12.4 Horizon Therapeutics Uric Acid-lowering Drugs Product Portfolio
- 8.12.5 Horizon Therapeutics Recent Developments
- 8.13 Fuji Yakuhin
- 8.13.1 Fuji Yakuhin Comapny Information
- 8.13.2 Fuji Yakuhin Business Overview
- 8.13.3 Fuji Yakuhin Uric Acid-lowering Drugs Sales, Value and Gross Margin (2020-2025)
- 8.13.4 Fuji Yakuhin Uric Acid-lowering Drugs Product Portfolio
- 8.13.5 Fuji Yakuhin Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Uric Acid-lowering Drugs Value Chain Analysis
- 9.1.1 Uric Acid-lowering Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Uric Acid-lowering Drugs Sales Mode & Process
- 9.2 Uric Acid-lowering Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Uric Acid-lowering Drugs Distributors
- 9.2.3 Uric Acid-lowering Drugs Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.